Featured publications
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
March 31, 2025
Horie K, Salvadó G, Koppisetti RK, Janelidze S, Barthélemy NR, He Y, Sato C, Gordon BA, Jiang H, Benzinger TLS, Stomrud E, Holtzman DM, Mattsson-Carlgren N, Morris JC, Palmqvist S, Ossenkoppele R, Schindler SE, Hansson O, Bateman RJ. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617-7. Epub ahead of print. PMID: 40164726.
Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype
July 1, 2023
Lawler PE, Bollinger JG, Schindler SE, Hodge CR, Iglesias NJ, Krishnan V, Coulton JB, Li Y, Holtzman DM, Bateman RJ. Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype. Anal Biochem. 2023 Jul 1;672:115156. doi: 10.1016/j.ab.2023.115156. Epub 2023 Apr 16. PMID: 37072097.
Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer’s Disease
June 1, 2023
Horie K, Li Y, Barthélemy NR, Gordon B, Hassenstab J, Benzinger TLS, Fagan AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Ikeuchi T, Kasuga K, Noble J, Farlow M, Chhatwal J, Day G, Schofield PR, Masters CL, Levin J, Jucker M, Lee JH, Roh JH, Sato C, Sachdev P, Koyama A, Reyderman L, Bateman RJ, McDade E; and the Dominantly Inherited Alzheimer Network. Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer’s Disease. Ann Neurol. 2023 Jun;93(6):1158-1172. doi: 10.1002/ana.26620. Epub 2023 Mar 16. PMID: 36843330; PMCID: PMC10238659.
Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based population
May 19, 2023
Li M, Li Y, Schindler SE, Yen D, Sutcliffe S, Babulal GM, Benzinger TLS, Lenze EJ, Bateman RJ. Design and feasibility of an Alzheimer’s disease blood test study in a diverse community-based population. Alzheimers Dement. 2023 May 19. doi: 10.1002/alz.13125. Epub ahead of print. PMID: 37204806.
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
April 1, 2023
Barthélemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, Stomrud E, Salvadó G, Janelidze S, Sato C, Ovod V, Henson RL, Fagan AM, Benzinger TLS, Xiong C, Morris JC, Hansson O, Bateman RJ, Schindler SE. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nat Aging. 2023 Apr;3(4):391-401. doi: 10.1038/s43587-023-00380-7. Epub 2023 Mar 13. PMID: 37117788; PMCID: PMC10154225.
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS
March 10, 2023
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS. Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26641. Epub ahead of print. PMID: 36897120.
Recent publications
- Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s diseaseDominantly Inherited Alzheimer Network (DIAN), Dec 2025, In: Alzheimer's Research and Therapy. 17, 1, 5.Research output: Contribution to journal › Article › peer-review
- Impact of genetic counseling and testing in individuals at high risk of familial Alzheimer's disease from Latin America: a non-randomized controlled trialBagnati, P. M., Londoño Castaño, M., Fernández, M. L., Henao, B. M., Chrem, P., Aguillón, D., Varela, L. E., Barbaran, J. D., Leon, Y., Surace, E., Madrigal, C. C., Picasso, J. P., Ramos, C. P., Fernández, C. M. R., Vigo, G., Aguilar, L. R., VargasCuadros, G. A., Arcos-Burgos, M., Longoria, E. M. & Ziegemeier, E. & 5 others, McDade, E., Bateman, R. J., Allegri, R. F., Lopera, F. & Llibre-Guerra, J. J., Apr 1 2025, In: Alzheimer's and Dementia: […]
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialDominantly Inherited Alzheimer's Disease–Trials Unit, Apr 2025, In: The Lancet Neurology. 24, 4, p. 316-330 15 p.Research output: Contribution to journal › Article › peer-review
- Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2Marsh, J. A., Huang, G., Bowling, K., Renton, A. E., Ziegemeier, E., Ball, T., Pottier, C., Cruchaga, C., Day, G., Bateman, R., Llibre-Guerra, J. J., McDade, E. & Karch, C. M., Apr 2025, In: Neurotherapeutics. 22, 3, e00527.Research output: Contribution to journal › Article › peer-review
- Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia researchIbanez, L., Liu, M., Beric, A., Timsina, J., Kohlfeld, P., Bergmann, K., Lowery, J., Sykora, N., Sanchez-Montejo, B., Brock, W., Budde, J. P., Bateman, R. J., Barthelemy, N., Schindler, S. E., Holtzman, D. M., Benzinger, T. L. S., Xiong, C., Tarawneh, R., Moulder, K. & Morris, J. C. & 2 others, Sung, Y. J. & Cruchaga, C., Feb 2025, In: Alzheimer's and Dementia. 21, 2, e14413.Research output: Contribution to journal › Article › peer-review
- A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsWarmenhoven, N., Salvadó, G., Janelidze, S., Mattsson-Carlgren, N., Bali, D., Orduña Dolado, A., Kolb, H., Triana-Baltzer, G., Barthélemy, N. R., Schindler, S. E., Aschenbrenner, A. J., Raji, C. A., Benzinger, T. L. S., Morris, J. C., Ibanez, L., Timsina, J., Cruchaga, C., Bateman, R. J., Ashton, N. & Arslan, B. & 4 others, Zetterberg, H., Blennow, K., Binette, A. P. & Hansson, O., Feb 1 2025, In: Brain. 148, 2, p. 416-431 16 p.Research output: Contribution to journal › Article › peer-review
- Gantenerumab in Dominantly Inherited Alzheimer Disease – ReplyWagemann, O., McDade, E. & Bateman, R. J., Jan 13 2025, In: JAMA Neurology. 82, 1, p. 111-112 2 p.Research output: Contribution to journal › Letter › peer-review
- Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s diseaseHorie, K., Salvadó, G., Koppisetti, R. K., Janelidze, S., Barthélemy, N. R., He, Y., Sato, C., Gordon, B., Jiang, H., Benzinger, T. L. S., Stomrud, E., Holtzman, D., Mattsson-Carlgren, N., Morris, J., Palmqvist, S., Ossenkoppele, R., Schindler, S., Hansson, O. & Bateman, R., 2025, (Accepted/In press) In: Nature medicine. e76494.Research output: Contribution to journal › Article › peer-review
- The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidenceAisen, P., Bateman, R. J., Crowther, D., Cummings, J., Dwyer, J., Iwatsubo, T., Kosco-Vilbois, M., McDade, E., Mohs, R., Scheltens, P., Sperling, R. & Selkoe, D., Jan 2025, In: Alzheimer's and Dementia. 21, 1, e14342.Research output: Contribution to journal › Article › peer-review
- Harnessing artificial intelligence to transform Alzheimer’s disease researchAndrieu, S., Bateman, R. J., Bereczki, E., Bose, N., Brookes, A. J., Doraiswamy, P. M., Kivipelto, M., Kohlhaas, S., Kourtis, L., Middleton, L. T., Moore, G. J., Petrella, J. R., Postlethwaite, N. & Sainz-Fuertes, R., 2025, (Accepted/In press) In: Nature medicine.Research output: Contribution to journal › Letter › peer-review